SCHEMBL4278670

SCHEMBL4278670

Cc1nc(Nc2nnc3cc(-c4cc(O)ccc4Cl)cc(C)c3n2)cc(N2CCN(CCO)CC2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 19/20 1.00
ABL1 P00519 6/20 0.58
YES1 P07947 3/20 0.58
KDR P35968 3/20 0.58
PDGFRB P09619 5/20 0.57
EPHB4 P54760 2/20 0.57
CIT O14578 1/20 0.57
GAK O14976 1/20 0.57
EPHB6 O15197 1/20 0.57
RIPK2 O43353 1/20 0.57
PRKD3 O94806 1/20 0.57
LCK P06239 1/20 0.57
RET P07949 1/20 0.57
BCR P11274 1/20 0.57
BRAF P15056 1/20 0.57
EPHA2 P29317 1/20 0.57
EPHB2 P29323 1/20 0.57
TYK2 P29597 1/20 0.57
ACVR1B P36896 1/20 0.57
TGFBR1 P36897 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15095306 0.93 SRC (0.87) SRCABL1YES1KDRPDGFRB
SCHEMBL4273929 0.90 SRC (0.82) SRCABL1YES1KDRPDGFRB
SCHEMBL4268507 0.86 SRC (1.00) SRCABL1YES1KDRPDGFRB
SCHEMBL4267475 0.85 SRC (1.00) SRCABL1YES1KDRPDGFRB
SCHEMBL4266657 0.81 SRC (1.00) SRCABL1YES1KDRPDGFRB
SCHEMBL41486 0.79 SRC (0.65) SRCABL1YES1KDRPDGFRB
SCHEMBL4264029 0.77 SRC (1.00) SRCABL1YES1KDRPDGFRB
SCHEMBL4266509 0.76 SRC (1.00) SRCABL1YES1KDRPDGFRB
Hydrochloric Acid SCHEMBL4275808 0.75 SRC (0.98) SRCABL1YES1KDRPDGFRB
SCHEMBL4270600 0.73 SRC (1.00) SRCABL1YES1KDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
EP-1809614-A2 BENZOTRIAZINE INHIBITORS OF KINASES Targegen, Inc. (US) 2007-07-25 EP disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 US disclosed
WO-2005096784-A2 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885
US-20090275569-A1 Benzotriazine Inhibitors of Kinases SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G SRC 1/4885ABL1 15/4885YES1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.